QUALIFIED FOR TARGETED DRUG DELIVERY

Pipeline

NEUWAY is preclinically developing an internal pipeline of EnPC-based therapeutics for treating severe orphan CNS diseases with very high medical need. This new therapeutic approach will have a transformative impact on the lives of patients suffering from orphan diseases with very limited treatment options.